Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Uneven Access & Privacy Issues Hamper Electronic Patient Healthcare Information Sharing

Linda Carroll  |  May 5, 2020

(Reuters Health)—Patient portals at U.S. hospitals leave a lot to be desired in terms of privacy when individuals want to share access with an informal caregiver, a new study finds. At nearly half of 102 hospitals included in the study, personnel advised that patients share their account password to give access to a family member…

Filed under:EMRsTechnology Tagged with:electronic health records (EHRs)privacySecurityTechnology

HCQ Prolongs QT Interval in Patients with COVID-19

Will Boggs, MD  |  May 5, 2020

NEW YORK (Reuters Health)—Potentially dangerous prolongation of the QT interval is common among patients hospitalized with COVID-19 who receive hydroxychloroquine (HCQ) with or without concomitant azithromycin, according to two new studies. “This is a well-known problem with HCQ and azithromycin, which became amplified in this higher risk population,” Christina F. Yen, MD, from Beth Israel…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19Hydroxychloroquine (HCQ)

Pharmacy Team Combats COVID-19 in NYC: Q&A with Mark J. Sinnett, PharmD, FASHP

Mary Choy, PharmD, BCGP, FASHP  |  May 1, 2020

The outbreak of the SARS-CoV-2 virus is disrupting patient care all over the world. In the U.S., many providers have had to adapt to new social distancing measures to care for patients, but struggles remain. Mark J. Sinnett, PharmD, FASHP, director of clinical and educational pharmacy services and director of the Center for Pharmacotherapy Research…

Filed under:Drug UpdatesProfessional Topics Tagged with:Association of Rheumatology Professionals (ARP)coronavirusCOVID-19Hydroxychloroquine (HCQ)pharmacysarilumabtocilizumab

Collaborating at the Leadership Level: Q&A with Lisa Fitzgerald, MD, & George Tsokos, MD

Carina Stanton  |  May 1, 2020

Rheumatology leaders are adapting to telemedicine and other modified collaborations to adjust patient care and research during the COVID-19 pandemic…

Filed under:Professional Topics Tagged with:collaborationcoronavirusCOVID-19Leadership

Transitioning to a Virtual Practice: Q&A with Lisa Criscione-Schreiber, MD, MEd

Carina Stanton  |  May 1, 2020

A quick shift to virtual teaching and patient care is just one of many changes rheumatologists at Duke University are adapting to during the COVID-19 pandemic…

Filed under:Practice Support Tagged with:coronavirusCOVID-19Practice Managementtelemedicine

Adapting Care for Pediatric Patients & Parents During the Pandemic: Q&A with Sangeeta Sule, MD, PhD

Susan Bernstein  |  May 1, 2020

Social distancing and telemedicine are creating unique challenges for pediatric rheumatologists to care for their patients—many of whom are 5 years old or younger. Sangeeta Sule, MD, PhD, discusses how her clinic is adapting…

Filed under:Conditions

Fear & Hope in the Era of the Modern Plague

Jose U. Scher, MD  |  April 29, 2020

This plague has affected each one of us, our families and friends, and abruptly, it has altered the way we relate to one another.

Filed under:OpinionSpeak Out Rheum Tagged with:COVID-19

3 U.S. Children with COVID-19 Have Rare Inflammatory Syndrome

Julie Steenhuysen  |  April 29, 2020

CHICAGO (Reuters)—Three U.S. children infected with the coronavirus are being treated for a rare inflammatory syndrome that appears similar to one that has raised concerns by doctors in Britain, Italy and Spain, a specialist treating the patients told Reuters. All three—who range in age from 6 months to 8 years—have undergone treatment at Columbia University…

Filed under:ConditionsPediatric Conditions Tagged with:coronavirusCOVID-19heartKawasaki diseasePediatric

Trial of Gilead’s Potential Coronavirus Treatment Running Ahead of Schedule

Deena Beasley  |  April 27, 2020

(Reuters)—A key U.S. government trial of Gilead Sciences Inc.’s experimental coronavirus treatment may yield results as early as mid-May, according to the study’s lead investigator, after doctors clamored to enroll their patients in the study. Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19Gileadremdesivir

U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19

Reuters Staff  |  April 27, 2020

(Reuters)—On April, the U.S. Food and Drug Administration (FDA) cautioned against the use of malaria drug hydroxychloroquine (HCQ) in COVID-19 patients even as President Donald Trump, who has touted it as a “game changer,” advocated for an additional review. The drug, first approved in 1955, provided no benefit and potentially higher risk of death for…

Filed under:Drug Updates Tagged with:coronavirusCOVID-19FDAHydroxychloroquine (HCQ)U.S. Food and Drug Administration (FDA)

  • « Previous Page
  • 1
  • …
  • 99
  • 100
  • 101
  • 102
  • 103
  • …
  • 324
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences